Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Torii Gets Japan Rights to Verrica’s Wart Drug
Torii Pharmaceutical, a subsidiary of Japan Tobacco, said on March 17 that it has exercised its option to acquire exclusive rights to develop and commercialize Verrica Pharmaceuticals’ skin disease drug candidate VP-102 in Japan. Under their pact, Torii will hold…
To read the full story
Related Article
- Torii Starts PIII Trial of Cantharidin for Common Warts
June 17, 2026
- Torii Gets Japan Option Rights to Verrica’s Warts Drug
August 6, 2020
BUSINESS
- M3’s MR-kun Hit by Data Breach, Pharma Staff and Doctors Exposed
October 16, 2026
- Santen Hits 93% Weekly AI Adoption in R&D, Digitizes Truckload of Research Records
October 16, 2026
- Medley Reports Cyberattack, Patient Data at Risk at Up to 787 Facilities
October 16, 2026
- Takeda’s TAK-881 Shaves 56 Minutes Off Infusion Time vs HyQvia
October 16, 2026
- UCB Japan Recalls Cimzia Over Needle Retraction Defect
October 16, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…